These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3289524)

  • 1. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.
    Wolkowitz OM; Breier A; Doran A; Kelsoe J; Lucas P; Paul SM; Pickar D
    Arch Gen Psychiatry; 1988 Jul; 45(7):664-71. PubMed ID: 3289524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
    Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
    Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alprazolam augmentation of antipsychotic pharmacotherapy?
    Thienhaus OJ; Somoza E; Nobilski M
    Arch Gen Psychiatry; 1989 Nov; 46(11):1052-3. PubMed ID: 2818141
    [No Abstract]   [Full Text] [Related]  

  • 5. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
    Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzodiazepines in schizophrenia: prefrontal cortex atrophy predicts clinical response to alprazolam augmentation.
    Seeley WW; Turetsky N; Reus VI; Wolkowitz OM
    World J Biol Psychiatry; 2002 Oct; 3(4):221-4. PubMed ID: 12516314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D; Labarca R; Linnoila M; Roy A; Hommer D; Everett D; Paul SM
    Science; 1984 Aug; 225(4665):954-7. PubMed ID: 6474162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia.
    Barbee JG; Mancuso DM; Freed CR; Todorov AA
    Am J Psychiatry; 1992 Apr; 149(4):506-10. PubMed ID: 1348161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.
    Csernansky JG; Riney SJ; Lombrozo L; Overall JE; Hollister LE
    Arch Gen Psychiatry; 1988 Jul; 45(7):655-9. PubMed ID: 3289523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task.
    Cohen RM; Nordahl TE; Semple WE; Andreason P; Litman RE; Pickar D
    Arch Gen Psychiatry; 1997 May; 54(5):481-6. PubMed ID: 9152102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trials of adjunctive alprazolam in "negative symptom" patients.
    Adan F; Siris SG
    Can J Psychiatry; 1989 May; 34(4):326-8. PubMed ID: 2736478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alprazolam augmentation of neuroleptics in schizophrenia.
    Wolkowitz OM; Breier A; Doran A; Lucas P; Kelsoe J; Paul SM; Pickar D
    Am J Psychiatry; 1989 Aug; 146(8):1087-8. PubMed ID: 2568762
    [No Abstract]   [Full Text] [Related]  

  • 15. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
    Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
    Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial.
    Siris SG; Morgan V; Fagerstrom R; Rifkin A; Cooper TB
    Arch Gen Psychiatry; 1987 Jun; 44(6):533-9. PubMed ID: 3555386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications.
    Kahn JP; Puertollano MA; Schane MD; Klein DF
    Am J Psychiatry; 1988 Jun; 145(6):742-4. PubMed ID: 2897166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluphenazine activity and antipsychotic response.
    Hitzemann RJ; Garver DL; Mavroidis M; Hirschowitz J; Zemlan FP
    Psychopharmacology (Berl); 1986; 90(2):270-3. PubMed ID: 3097710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
    Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.